ARTHROSAMID® by contura ORTHOPAEDICS

iPAAG

Introducing Arthrosamid® — a new class of injectable therapy to treat knee OA

Offering patients an effective alternative to current therapies for knee OA, Arthrosamid® is an injectable polyacrylamide hydrogel (iPAAG) for intra-articular administration.

A non-biodegradable injectable implant, Arthrosamid® delivers **long-acting pain relief** — improving the quality of life for patients with knee osteoarthritis.[1]

Study recruitment starting

LUNA
Intra-Articular Arthrosamid® Injection in Subjects with Knee OA Prospective, Long-Term, Observational, All-Comers, Open-Label, Multi-Centre Clinical Investigation

ARTHROSAMID INJECTION FOR OA KNEE
Mechanistic and Clinical Study of Intra-articular Arthrosamid for Knee Osteoarthritis, Single Site, Open-Label, Assessing changes in (WOMAC) score between baseline (pre-injection) and 6 months and 12 months post-injection

IDA has a study extension up to 5 years with data published annually



Simple

A minimally invasive out-patient procedure performed under local anaesthesia, with ultrasound guidance.[8]

Safe

Arthrosamid® is safe for intended use[4]— and has undergone over 20 years of research and development.[9]

Sustained

In clinical trials, patients reported a reduction in pain by Week 4.
This reduction was sustained over 2 years.[6]

iPAAG: Injectable polyacrylamide hydrogel

A prospective study of polyacrylamide hydrogel injection (iPAAG) for knee osteoarthritis

Results from 104 weeks after treatment (IDA 2 years)[9,6]



Statistically significant reduction in pain maintained at 2 years.[6]

One-year performance of polyacrylamide hydrogel (iPAAG) vs. hyaluronic acid

Analysis of change from baseline of subgroup <70 years (ROSA)[9,10]



Significant difference in change from baseline between Arthrosamid® and Synvisc-One® at 52 weeks.[10]

† WOMAC or The Western Ontario and McMaster Universities Osteoarthritis Index is a measure of symptoms and physical disability LSMeans are modelled/estimated means. The estimated means are using data from the other visits and also the covariates. Synvisc-One is a registered trademark of Sanofi-Aventis U.S. LLC. Arthrosamid is a registered trademark of Contura International A/S. © copyright 2022 Contura International Ltd.

@ConturaLtd Contura-Orthopaedics-Ltd Contura Orthopaedics Ltd

Safety of intra-articular polyacrylamide hydrogel (iPAAG) for the treatment of knee osteoarthritis symptoms

	DAISY 2019 104 weeks[4,9]	IDA 2021 26 weeks[1,9]	IDA 2021 52 weeks[5,9]	IDA 2022 104 weeks[6,9]	ROSA 2022 52 weeks[7,9]
ITT	91	49	49	49	121
Number of AE device related	**41**	**14**	**16**	**14**	**41**
Sensation of distension	15	-	-	-	-
Pain from target knee	7	7	6	6	21
Reduced range of motion	4	-	-	-	-
Joint swelling	-	3	4	4	13
Other	15	4	6	4	7

"No intra-articular infections or allergic reactions were reported in this retrospective study."[4]

"No patients had severe adverse events linked to Arthrosamid®."[1]

References: 1. Bliddal, H., *et al.* (2021). *Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: A 6 Months Prospective Study. J Orthop Res Ther.* 6(2). 1188. ISSN 2575-8241; **2.** Tnibar, A,. *et al.* (2015). An international multi-centre prospective study on the efficacy of an intraarticular polyacrylamide hydrogel in horses with osteoarthritis: a 24 months follow-up. *Acta Vet Scand.* Apr 15;57(1):20. doi: 10.1186/s13028-015-0110-6; **3.** Henriksen, M., *et al.* (2018). Intra-articular 2.5% polyacrylamide hydrogel for the treatment of knee osteoarthritis: an observational proof-of-concept cohort study. *Clin Exp Rheumatol.* Nov-Dec;36(6):1082-1085. Epub 2018 Jul 18. PMID: 30148430; **4.** Overgaard, A., *et al.* (2019). Safety of intra-articular polyacrylamide hydrogel for the treatment of knee osteoarthritis symptoms: A retrospective case series. *Clin Ortho Adv Res;* **5.** Bliddal, H., *et al.* (2021). Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: Results of a 52 Week Prospective Study. *Osteoarthritis and Cartilage* Vol.29 S278; **6.** Bliddal, H., *et al.* (2022). A Prospective Study of Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: Results From 2 Years After Treatment. Poster presented at OARSI 2022; **7.** Bliddal, H., *et al.* (2022). One-year performance of polyacrylamide hydrogel vs. hyaluronic acid: A randomised controlled study. Poster presented at OARSI 2022; **8.** Arthrosamid®, Instructions For Use. Release Date March 2022 10082-003; **9.** Data on file; **10.** Bliddal, H., *et al.* (2022). One-year performance of polyacrylamide hydrogel vs. hyaluronic acid in age, BMI, and Kellgren-Lawrence subgroups: A subgroup analysis of a randomised study. Poster presented at OARSI 2022.

OUS/ARTHRO/NOV2022/112

For full details about warnings and precautions read the IFU. For more information and the IFU please visit **www.Arthrosamid.com** or contact us at **enquiries@Arthrosamid.com**

www.**Arthrosamid**.com